Cellectar Biosciences Inc (CLRB)

[Sluicebox]

Yes there is a big chance that CLR131 can be monetized in real life. Considering the huge potential compared with a crazy low Mcap, I consider this a value investment

[Sluicebox]

Yes there is a big chance that CLR131 can be monetized in real life. Considering the huge potential compared with a crazy low Mcap, I consider this a value investment

[Crusader]

What’s up here, traders?

CLRBZ (warrants) are up over 50% today on the heaviest volume in months for those warrants @ .17?

Why accumulate this POS? Unless, ....Naaaaa...CLR131 can be monetized for doing good in the real world for very sick MM patients!!!

[Crusader]

What’s up here, traders?

CLRBZ (warrants) are up over 50% today on the heaviest volume in months for those warrants @ .17?

Why accumulate this POS? Unless, ....Naaaaa...CLR131 can be monetized for doing good in the real world for very sick MM patients!!!

[Sluicebox]

Ups you'r right.

[Rymankoly]

He got free options (not a buy):
https://ih.advfn.com/stock-market/NASDAQ/cellectar-biosciences-CLRB/stock-news/82796093/statement-of-changes-in-beneficial-ownership-4

[Sluicebox]

VP CMO buys 100000 shares at 1.34. I will be buying on any dip and look forward to impressive PH II data readout shortly. This readout will confirm earlier efficacy and ignite road to quick aproval, with the orphans drug status. I los look forward to a $100 M priority voucher which is 4 x Mcap :-o

[Sluicebox]

New PT from Oppenheimer $5 outperform

[Sluicebox]

It's a real shame about the watering out of shareholders during the last many year, happy I was not part of that. And the mgm might not be the best.

But it doesn't change the fact that CLR-131 is a very interesting candidate with some very exiting trial results.
Just revisited their lates clinical presentation and think it is good news all around.
Just the fact that the MOA of CLR-131 is unique makes it relevant in later lines.


I look forward to the Clover-1 trial that will hopefully readout beginning of Q3. Strongly believe that the 2-cycle dosing will show solid results.

Also looking forward to update on phase I Pediatric Brain & Solid Tumors.

[Sunofwolf]

correct its only purpose is to pay for a fancy office in NJ for a Fat CEO who has done nothing but lose money for investors.-has zero income except for the fools that buy this garbage. Anything the company puts out is rubbish

[Jonnyo07]

Cellectar is garbage!

[stockguard]

7:44 am ET June 23, 2020
Cellectar Biosciences started at buy with $3 stock price target at Maxim Group

Maxim analyst Jason McCarthy initiated coverage of Cellectar Biosciences with a Buy rating and $3 price target. The analyst says the data in the company's development of phospholipid drug conjugates to target cancer's "addiction" to phospholipids have been "compelling". McCarthy further notes additional catalysts expected in the second half of 2020 and in 2021, with "updates on a pediatric study in solid tumors and r/r blood cancers", adding that Cellectar should also have cash runway well into 2021

[Sluicebox]

Finally - money on the book to drive forward with CLR131, which looks very promising. Looking forward to update on two-cycle dosing cohort. Cheap and effective especially in the later lines where there are no alternatives for R/R MM R/R NHL having failed on tripple and quadruple combi and almost everything we can throw at these patients. Worth a listen https://viavid.webcasts.com/viewer/event.jsp?ei=1278219&tp_key=119af7bc64

[S3lfMade]

Company selling shares, most likely.

Most bios are in nonstop dilution mode.

[cash_cow1]

Why did it take a nose dive on opening bell. The News was great and it just skirted right off the road into a ditch. lol !

[S3lfMade]

CLR 131 is a radiotherapy designed to directly target cancer cells and limit exposure to healthy cells, unlike traditional treatment options.

[Crusader]

$5 Clover study of CLR131?

SonofGun!

[TTIME]

$CLRB , Great News !!

[Bula Vinaka]

How do you get in all this big plays before it happens SM?

[crudeoil24]

LOL. Your present today is an algo G&T.

[TheFinalCD]

Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia



https://www.globenewswire.com/news-release/2020/05/26/2038539/0/en/Cellectar-Receives-FDA-Fast-Track-Designation-for-CLR-131-in-Lymphoplasmacytic-Lymphoma-Waldenstrom-s-Macroglobulinemia.html

[Sunofwolf]

CEO needs to be Fired,he done Zero except spend shareholders money on himself! Company is a fraud and its research a smoke screen. Doesn't deserve a penny, just go out of any business because nothing will ever happen here, except fake news release's and selling more stock.

[Crusader]

Before the well is poisoned more

by resident bears, consider this Seeking Alpha article about biotech companies capitalizing their developments. The story is NOT finished here even if short bears will not go away and stop saving us from ourselves.

Expected capital raises continue to ramp in healthcare amid pandemic
May 09, 2020 12:40 PM ETCheck-Cap Ltd. (CHEK)2 Comments
The need for capital continues apace for healthcare companies as they deal with COVID-19 disruptions.
Stock offerings:
Check-Cap (NASDAQ:CHEK): direct placement of 5M ordinary shares at $0.60 per share plus 5 1/2-year warrants to purchase up to 5M shares at $0.80. Friday's close was $0.54.
Cellectar Biosciences (NASDAQ:CLRB): $17.5M public offering of stock and five-year warrants.
Mixed shelf filings:
BioTelemetry (NASDAQ:BEAT): unspecified.
Clearside Biomedical (NASDAQ:CLSD): $250M.
Arcturus Therapeutics (NASDAQ:ARCT): $200M.
Mersana Therapeutics (NASDAQ:MRSN): $250M.

CLRB’s DILUTION IS HUNDREDS OF TIMES SMALLER THAN THOSE OTHERS LISTED.

The real issue is a cure; no the cost of getting there!

[Sunofwolf]

Worthless company.

[Sunofwolf]

This company's sells shares to pay for everything, including a fancy office in NJ for a fat CEO. Any one holding shares gets diluted stock. Any drug they claim they are working on is a scam! As is the entire briefcase company is. They use to make some products , now they have someone else claim to be making the drugs. This company is a Fraud.

[Sluicebox]

Love the simplicity of their drug, but still no financing in place ? Once they have financing in place I am a buyer

[Sunofwolf]

Ha Ha this junk is done!

[Sunofwolf]

Down a 100% from a fake high-this company has nothing of value at all. Investors only lose here.

[Sunofwolf]

Good go to nothing!

[Sunofwolf]

no one will even Mod this company anymore. Everyone lost dough and the CEO is sitting in NJ in a fancy office feet up on chair smoking and laughing at the sukers.

[Sunofwolf]

gov allows these phony companies to exist-Snake Oil.

[Sunofwolf]

100% cash-won't trade anything anymore to these crooks!

[zigland]

Projected for a strong rebound

[Crusader]

BAD NEWS COMING NEXT HOUR:

I am outta here.

Wolf, takes over as your cheerleader.

Crusader OUT!

[Crusader]

BAD NEWS COMING NEXT HOUR:

I am outta here.

Wolf, takes over as your cheerleader.

Crusader OUT!

[Crusader]

Bingo !

$3.04 printed...thank you to Art Cashin @ UBS.

[Crusader]

$3 price per share? Accumulation!

If so, the new screen names will show up here in this ghost town, and I will stop talking to myself and Wolf.

One last important point, cheap leverage in CLRB is available now in warrants: CLRBZ, currently selling at 10 cents per warrant that expire in April 2021. Could be a quick one or two bagger next week, or not. LOL

[Crusader]

UBS Switzerland buying CLRB:

http://archive.fast-edgar.com//20200211/A32ZE22CZW2RJJZ222262ZYRT5J3ZZ223I22/

[Crusader]

6 more days to wait for fog to clear:

Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

BY GlobeNewswire
— 8:00 AM ET 01/09/2020

FLORHAM PARK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences ( CLRB
Cellectar Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will host a Clinical Data Call on Wednesday, February 19, 2020 at 10:30 am Eastern Time.

Members of Cellectar’s senior management team and Dr. Sikander Ailawadhi, M.D., the lead investigator for the company’s Phase 2 study, will provide additional clinical data, as well as an update and analysis of the CLR 131 Phase 1 and Phase 2 hematology focused trials. The team will also provide a summary of the data for patients with relapsed/refractory B-cell malignancies, including patients with multiple myeloma and select non-Hodgkins lymphoma. Additionally, the team will review the current treatment landscape and unmet medical need for treating patients with these cancers, and provide an overview of the market opportunity and its clinical development plan for CLR 131.

Sikander Ailawadhi, M.D. is an Associate Professor, Division of Hematology/Oncology at Mayo Clinic Florida and is the lead investigator for the company’s Phase 2 CLOVER-1 trial of CLR 131 in patients with relapsed/refractory B-cell hematologic cancers. Dr. Ailawadhi was awarded the 2013 NCI CCITLA as an Assistant Professor of Medicine at the Norris Cancer Center, University of Southern California (USC), Los Angeles CA. Subsequently, he joined the Division of Hematology and Oncology at Mayo Clinic in Florida as a Senior Associate Consultant in order to pursue his career goal of clinical, translational and outcomes-based research in B-cell malignancies, especially plasma cell disorders.

[murocman]

That’s the plan. 99% of biotechs in the clinical stage are not worth any kind of long hold.

They are news driven and dilute to often

[Sunofwolf]

get your money then drop the hammer.

[murocman]

Catalyst coming up. I think not.

GLTU,

Murocman

[Sunofwolf]

Watch out at any trading day this stock will tank like a rock thrown out of a tall building.

[Sunofwolf]

this stock is not worth what its trading at and will do nothing but go way down!

[Crusader]

X$2.80 close after hours market 2/4/20...

[Crusader]

$2.78 morning high; who is accumulating here?

Could it be some of these smart money folks or some retail investors other than Sunofwolf.

There was a single 10,000 share purchase of CLRB IN THE OPENING HOUR OF TRADING TODAY.

Cellectar BioSciences Inc, Inst Holders, 4Q 2019 (CLRB)
BY Dow Jones & Company, Inc.
— 3:50 AM ET 01/22/2020

The following table shows the largest shareholders in CELLECTAR BIOSCIENCES INC COM (CLRB) for the quarter ended December 31, 2019, listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 12/31/2019
Institution Shares Shares % Last
Held Changed Held Report


Tavistock Life Sciences Co. (I 920,000 0 9.791 09/30
Tang Capital Management LLC 235,701 (444,299) 2.509 09/30
Renaissance Technologies LLC 176,902 53,854 1.883 09/30
Sphera Funds Management Ltd. 87,500 0 0.931 09/30
Morgan Stanley Smith Barney LL 32,221 (3,000) 0.343 09/30
The Vanguard Group Inc. 16,755 0 0.178 09/30
Private Advisor Group LLC 13,400 0 0.143 09/30
JPMorgan Securities LLC (Inves 10,505 10,505 0.112 09/30

[Crusader]

For cheap LEVERAGE: Remember CLRBZ

April 2021 Warrants currently trading at $.15 this am.

CLRBZ 52 week high near one dollar per. Leverage!

CLRBZ before 2-19-20 press release of more clinical trial data.

THERE MUST BE SOME INSIDER INFORMATION BEHIND THE RECENT CLRB ACCUMULATION!!!


CLRB TRADING AT $2.79 pps THIS MORNING, UP ALMOST 5 %

[Crusader]

There's something happening here

What it is ain't exactly clear
There's a man with a gun over there
Telling me I got to beware

REMEMBER FEBRUARY 19, 2020 for more clinical trial data.

[Sunofwolf]

time for the company to sell out the investor!

[Sunofwolf]

another stock reverse can happen at any time destroying your share value-crooks.